8-K: Liminatus Pharma Settles Warrants with Alta Partners, Issues New Shares

Liminatus Pharma, Inc. entered into a settlement agreement with Alta Partners, LLC, issuing 350,000 shares of common stock in exchange for the cancellation of 1,000,000 warrants.

Summary

• Liminatus Pharma, Inc. (the Company) executed a settlement and release agreement with Alta Partners, LLC (the Holder) on July 16, 2025.
• Under the agreement, the Company will issue 350,000 shares of its common stock, with a par value of $0.0001 per share, to Alta Partners, LLC.
• In return for the shares, Alta Partners, LLC will surrender and cancel 1,000,000 warrants to purchase shares of the Company's common stock.
• No commission or other remuneration was paid, directly or indirectly, in connection with this exchange.
• The issuance of these shares was not registered under the Securities Act of 1933, relying on the exemption provided by Section 3(a)(9) of the Act.

Sentiment

Score: 6

Explanation: The settlement resolves an outstanding warrant obligation, which is positive for capital structure clarity. However, it involves immediate share dilution, which is a negative. The net effect is moderately positive as it cleans up the cap table by exchanging a larger potential future dilution for a smaller immediate one, assuming the warrants were in-the-money or near-money.

Positives

• The cancellation of 1,000,000 warrants reduces the potential future dilutive effect that these specific warrants could have had on the Company's stock.
• The settlement resolves an outstanding obligation or potential dispute with a significant holder, Alta Partners, LLC.

Negatives

• The issuance of 350,000 new shares of common stock results in immediate dilution for existing shareholders.

Risks

• The issuance of shares under Section 3(a)(9) of the Securities Act means these shares were not registered, which could have implications for their resale by the holder, though not explicitly stated as a risk to the company in the document.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding future financial performance or strategic direction beyond the immediate transaction.

Management Comments

• Chris Kim, Chief Executive Officer, signed the report on behalf of Liminatus Pharma, Inc.

Industry Context

This transaction is a specific corporate finance action related to managing the company's capital structure and outstanding equity instruments. It does not directly reflect broader industry trends or competitive dynamics, but rather a resolution of a specific financial arrangement.

Legal Proceedings

• The 'settlement and release agreement' implies the resolution of a prior dispute or obligation, though no details of ongoing litigation are provided.

Stakeholder Impact

• Shareholders: Experience immediate dilution due to the issuance of 350,000 new shares, but benefit from the cancellation of 1,000,000 warrants, reducing potential future dilution from those specific instruments.

Key Dates

Keywords

Liminatus Pharma, Alta Partners, Settlement Agreement, Warrant Cancellation, Share Issuance, Common Stock, SEC Filing, Form 8-K, Equity Securities, Dilution